These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37461560)

  • 1. Dual targeting of hepatocyte DGAT2 and stellate cell FASN alleviates nonalcoholic steatohepatitis in mice.
    Yenilmez B; Harney S; DiMarzio C; Kelly M; Min K; Echeverria D; Bramato BM; Jackson SO; Reddig K; Kim JK; Khvorova A; Czech MP
    bioRxiv; 2023 Jul; ():. PubMed ID: 37461560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lactate transporter MCT1 in hepatic stellate cells promotes fibrotic collagen expression in nonalcoholic steatohepatitis.
    Min K; Yenilmez B; Kelly M; Echeverria D; Elleby M; Lifshitz LM; Raymond N; Tsagkaraki E; Harney SM; DiMarzio C; Wang H; McHugh N; Bramato B; Morrison B; Rothstein JD; Khvorova A; Czech MP
    Elife; 2024 Apr; 12():. PubMed ID: 38564479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lactate transporter MCT1 in hepatic stellate cells promotes fibrotic collagen expression in nonalcoholic steatohepatitis.
    Min K; Yenilmez B; Kelly M; Echeverria D; Elleby M; Lifshitz LM; Raymond N; Tsagkaraki E; Harney SM; DiMarzio C; Wang H; McHugh N; Bramato B; Morrision B; Rothstein JD; Khvorova A; Czech MP
    bioRxiv; 2023 Oct; ():. PubMed ID: 37205462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis.
    Yenilmez B; Wetoska N; Kelly M; Echeverria D; Min K; Lifshitz L; Alterman JF; Hassler MR; Hildebrand S; DiMarzio C; McHugh N; Vangjeli L; Sousa J; Pan M; Han X; Brehm MA; Khvorova A; Czech MP
    Mol Ther; 2022 Mar; 30(3):1329-1342. PubMed ID: 34774753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models.
    O'Farrell M; Duke G; Crowley R; Buckley D; Martins EB; Bhattacharya D; Friedman SL; Kemble G
    Sci Rep; 2022 Sep; 12(1):15661. PubMed ID: 36123383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
    Wang Q; Zhou H; Bu Q; Wei S; Li L; Zhou J; Zhou S; Su W; Liu M; Liu Z; Wang M; Lu L
    J Hepatol; 2022 Aug; 77(2):312-325. PubMed ID: 35292349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
    Park HS; Song JW; Park JH; Lim BK; Moon OS; Son HY; Lee JH; Gao B; Won YS; Kwon HJ
    Autophagy; 2021 Sep; 17(9):2549-2564. PubMed ID: 33190588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin alleviates diet-induced steatohepatitis by targeting multiple cell types in the liver to suppress inflammation and fibrosis.
    Xu L; Li H; Zhang O; Zhang F; Song M; Ma M; Zhao Y; Ding R; Li D; Dong Z; Jin S; Han W; Ding C
    J Mol Endocrinol; 2023 Jan; 70(1):. PubMed ID: 36356262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
    J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice.
    Yang A; Yan X; Fan X; Shi Y; Huang T; Li W; Chen W; Jia J; You H
    Hepatol Int; 2021 Oct; 15(5):1122-1135. PubMed ID: 34014450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAF15 exacerbates nonalcoholic steatohepatitis progression by regulating lipid metabolism and inflammation via FASN and p65 NF-κB.
    Yang S; Xu B; Han Y; Jiang M; Luo T; Wu N; Cao J; Zheng Y; Shen L; Qin W; Shi H; Dong L
    Liver Int; 2023 Sep; 43(9):1920-1936. PubMed ID: 37183512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of fatty acid synthase in nonalcoholic fatty liver disease.
    Dorn C; Riener MO; Kirovski G; Saugspier M; Steib K; Weiss TS; Gäbele E; Kristiansen G; Hartmann A; Hellerbrand C
    Int J Clin Exp Pathol; 2010 Mar; 3(5):505-14. PubMed ID: 20606731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte-targeted siTAZ therapy lowers liver fibrosis in NASH diet-fed chimeric mice with hepatocyte-humanized livers.
    Wang X; Moore MP; Shi H; Miyata Y; Donnelly SK; Radiloff DR; Tabas I
    Mol Ther Methods Clin Dev; 2023 Dec; 31():101165. PubMed ID: 38144682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Squalene Epoxidase Induces Nonalcoholic Steatohepatitis Via Binding to Carbonic Anhydrase III and is a Therapeutic Target.
    Liu D; Wong CC; Zhou Y; Li C; Chen H; Ji F; Go MYY; Wang F; Su H; Wei H; Cai Z; Wong N; Wong VWS; Yu J
    Gastroenterology; 2021 Jun; 160(7):2467-2482.e3. PubMed ID: 33647280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2).
    Sharma RS; Harrison DJ; Kisielewski D; Cassidy DM; McNeilly AD; Gallagher JR; Walsh SV; Honda T; McCrimmon RJ; Dinkova-Kostova AT; Ashford MLJ; Dillon JF; Hayes JD
    Cell Mol Gastroenterol Hepatol; 2018 Mar; 5(3):367-398. PubMed ID: 29552625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIF Differentially Regulates Hepatic Steatosis and Inflammation/Fibrosis in Mice.
    Yang L; Miura K; Zhang B; Matsushita H; Yang YM; Liang S; Song J; Roh YS; Seki E
    Cell Mol Gastroenterol Hepatol; 2017 May; 3(3):469-483. PubMed ID: 28462384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
    Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
    Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte Deletion of Triglyceride-Synthesis Enzyme Acyl CoA: Diacylglycerol Acyltransferase 2 Reduces Steatosis Without Increasing Inflammation or Fibrosis in Mice.
    Gluchowski NL; Gabriel KR; Chitraju C; Bronson RT; Mejhert N; Boland S; Wang K; Lai ZW; Farese RV; Walther TC
    Hepatology; 2019 Dec; 70(6):1972-1985. PubMed ID: 31081165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Notch1 inhibits the mechanistic role of STING signaling to regulate hepatocyte lipophagy in nonalcoholic steatohepatitis].
    Yang T; Zhao JY; Wang X; Fang ZG; Jiang LF; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):827-834. PubMed ID: 37723064
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis.
    Widjaja AA; Singh BK; Adami E; Viswanathan S; Dong J; D'Agostino GA; Ng B; Lim WW; Tan J; Paleja BS; Tripathi M; Lim SY; Shekeran SG; Chothani SP; Rabes A; Sombetzki M; Bruinstroop E; Min LP; Sinha RA; Albani S; Yen PM; Schafer S; Cook SA
    Gastroenterology; 2019 Sep; 157(3):777-792.e14. PubMed ID: 31078624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.